CRIS Current Research Information System

ISIDORI, ALESSANDRO
 Distribuzione geografica
Salva come PNG Salva come JPEG
Continente #
NA - Nord America 2.420
AS - Asia 1.938
EU - Europa 1.475
Continente sconosciuto - Info sul continente non disponibili 128
SA - Sud America 103
AF - Africa 97
OC - Oceania 4
Totale 6.165
Salva come PNG Salva come JPEG
Nazione #
US - Stati Uniti d'America 2.370
SG - Singapore 539
VN - Vietnam 489
CN - Cina 459
GB - Regno Unito 298
SE - Svezia 244
IT - Italia 217
DE - Germania 196
HK - Hong Kong 124
FR - Francia 98
IN - India 94
BR - Brasile 74
UA - Ucraina 69
RU - Federazione Russa 66
IE - Irlanda 62
NL - Olanda 56
FI - Finlandia 38
JP - Giappone 37
TG - Togo 36
BD - Bangladesh 29
KR - Corea 29
ZA - Sudafrica 29
BG - Bulgaria 27
CA - Canada 26
CH - Svizzera 25
ID - Indonesia 22
JO - Giordania 20
EE - Estonia 19
CI - Costa d'Avorio 17
BE - Belgio 16
EU - Europa 16
PH - Filippine 15
TR - Turchia 12
TH - Thailandia 11
MX - Messico 10
AR - Argentina 9
GR - Grecia 9
SA - Arabia Saudita 9
ES - Italia 8
IR - Iran 8
TW - Taiwan 8
IQ - Iraq 7
CO - Colombia 6
LB - Libano 6
PL - Polonia 6
SC - Seychelles 6
CR - Costa Rica 5
MY - Malesia 5
UZ - Uzbekistan 5
AU - Australia 4
EC - Ecuador 4
PY - Paraguay 4
RO - Romania 4
AT - Austria 3
GT - Guatemala 3
HR - Croazia 3
PE - Perù 3
PK - Pakistan 3
SV - El Salvador 3
BO - Bolivia 2
CZ - Repubblica Ceca 2
JM - Giamaica 2
MA - Marocco 2
OM - Oman 2
TN - Tunisia 2
AE - Emirati Arabi Uniti 1
AL - Albania 1
CG - Congo 1
CL - Cile 1
CY - Cipro 1
DZ - Algeria 1
EG - Egitto 1
ET - Etiopia 1
GD - Grenada 1
GI - Gibilterra 1
HU - Ungheria 1
IL - Israele 1
LT - Lituania 1
LU - Lussemburgo 1
MG - Madagascar 1
MK - Macedonia 1
PS - Palestinian Territory 1
PT - Portogallo 1
RS - Serbia 1
SK - Slovacchia (Repubblica Slovacca) 1
SY - Repubblica araba siriana 1
Totale 6.053
Salva come PNG Salva come JPEG
Città #
Singapore 384
Ashburn 293
Southend 251
Chandler 190
Fairfield 179
Dong Ket 128
San Jose 128
Woodbridge 119
Hong Kong 114
Houston 105
Wilmington 103
Seattle 99
Ho Chi Minh City 96
Hanoi 89
Ann Arbor 88
Beijing 79
Santa Clara 79
Cambridge 76
Hefei 73
Princeton 63
Dublin 60
New York 55
Jacksonville 46
Los Angeles 45
Boardman 42
Council Bluffs 36
Lomé 36
Tokyo 31
Lauterbourg 29
Bologna 27
Helsinki 27
Nanjing 27
Sofia 27
Westminster 27
Berlin 25
Seoul 24
Bremen 23
Bern 22
Hyderabad 22
Frankfurt am Main 21
Amman 20
Milan 18
Padova 18
Abidjan 17
Turin 17
Chicago 16
Dallas 16
Munich 16
Brussels 15
Da Nang 15
San Diego 15
Buffalo 14
Haiphong 14
Jinan 13
Norwalk 13
São Paulo 11
Guangzhou 10
Orem 10
Zhengzhou 10
Redmond 9
Redondo Beach 9
Saint Petersburg 9
Changsha 8
Jakarta 8
Jiaxing 8
Mülheim 8
Phoenix 8
Rome 8
Tianjin 8
Bengaluru 7
Olalla 7
Salsomaggiore Terme 7
Shenyang 7
Toronto 7
Turku 7
Yubileyny 7
Brooklyn 6
Hebei 6
London 6
Mexico City 6
Montreal 6
Nanchang 6
Verona 6
Bangkok 5
Changchun 5
Des Moines 5
Falls Church 5
Johannesburg 5
Mahé 5
Naples 5
San Francisco 5
Tashkent 5
Amsterdam 4
Biên Hòa 4
Chengdu 4
Chennai 4
Chongqing 4
Falkenstein 4
Foshan 4
Hangzhou 4
Totale 3.917
Salva come PNG Salva come JPEG
Nome #
Generation of dendritic cells from positively selected CD14+ monocytes for anti-tumor immunotherapy. 275
Acute myeloid leukemia cells constitutively express the immunoregulatory enzyme indoleamine 2,3-dioxygenase. 260
Phase II study of a single pegfilgrastim injection as an adjunct to chemotherapy to mobilize stem cells into the peripheral blood of pretreated lymphoma patients. 238
Durability of spleen response affects the outcome of ruxolitinib-treated patients with myelofibrosis: Results from a multicentre study on 284 patients 234
NUCLEOFECTION IS AN EFFICIENT NON-VIRAL TRANSFECTION TECHNIQUE FOR HUMAN BONE MARROW-DERIVED MESENCHYMAL STEM CELLS. 229
Genetic profiling in acute myeloid leukemia: a path to predicting treatment outcome 222
Successful transfer of alloreactive haploidentical KIR ligand-mismatched natural killer cells after infusion in elderly high risk acute myeloid leukemia patients. 221
Impact of comorbidities and body mass index in patients with myelofibrosis treated with ruxolitinib 221
No preferential sensitivity of t(8;21) acute myeloid leukemias to cytosine arabinoside in vitro: is intensity of therapy or high dose Ara-C crucial for response? 210
Efficacy and safety of ruxolitinib in intermediate-1 IPSS risk myelofibrosis patients: Results from an independent study 210
Gemtuzumab ozogamicin for relapsed and refractory acute myeloid leukemia and myeloid sarcomas 209
Association of 3q21q26 syndrome with different RPN1/EVI1 fusion transcripts 199
Low-dose lenalidomide plus cytarabine in very elderly, unfit acute myeloid leukemia patients: Final result of a phase II study 196
Epidemiology, outcome, and risk factors for infectious complications in myelofibrosis patients receiving ruxolitinib: A multicenter study on 446 patients 195
Chemotherapy-Induced Tumor Cell Death at the Crossroads Between Immunogenicity and Immunotolerance: Focus on Acute Myeloid Leukemia 193
Stem cell mobilization and collection in patients with liver cirrhosis. 187
Dendritic cell differentiation. 185
Modulation of tryptophan catabolism by human leukemic cells results in the conversion of CD25- into CD25+ T regulatory cells. 185
Interleukin-12 production by leukemia-derived dendritic cells counteracts the inhibitory effect of leukemic microenvironment on T cells. 181
Ruxolitinib in elderly patients with myelofibrosis: impact of age and genotype. A multicentre study on 291 elderly patients 180
Autologous stem cell transplantation for acute myeloid leukemia patients in first complete remission: a 10-year follow-up study of 118 patients. 172
Gene expression profile predicts response to the combination of tosedostat and low-dose cytarabine in elderly AML 161
Life after ruxolitinib: Reasons for discontinuation, impact of disease phase, and outcomes in 218 patients with myelofibrosis 160
Impact of 2016 WHO diagnosis of early and overt primary myelofibrosis on presentation and outcome of 232 patients treated with ruxolitinib. 158
Impact of calreticulin mutations on treatment and survival outcomes in myelofibrosis during ruxolitinib therapy 155
Metabolic Switch and Cytotoxic Effect of Metformin on Burkitt Lymphoma 151
Consolidation therapy for adult acute myeloid leukemia: A systematic analysis according to evidence based medicine 144
The Yin and Yang of the Bone Marrow Microenvironment: Pros and Cons of Mesenchymal Stromal Cells in Acute Myeloid Leukemia 142
Persistent immune stimulation exacerbates genetically driven myeloproliferative disorders via stromal remodeling 141
Ponatinib as second-line treatment in chronic phase chronic myeloid leukemia patients in real-life practice 134
Molecular monitoring of acute myeloid leukemia associated with inv(16): Threshold of CBFβ/MYH11 transcript copy number above which relapse occurs and below which continuous complete remission is likely (multiple letters) [8] 122
Erratum: Phase II study of a single pegfilgrastim injection as an adjunct to chemotherapy to mobilize stem cells into the peripheral blood of pretreated lymphoma patients (Haematologica (2005) 90, (225-231). 87
Two more inv(16) acute myeloid leukemia cases with infrequent CBFβ-MYH11 fusion transcript: Clinical and molecular findings [4] 77
The role of menin inhibitors in acute myeloid leukemia 62
Impact of fitness categorization according to SIE/SIES/GITMO criteria in therapy-related and AML-MRC receiving CPX-351 42
Clinical benefit and predictors of response to momelotinib after ruxolitinib failure: A cooperative real‐world study 27
Totale 6.165
Salva come PNG Salva come JPEG
Categoria #
all - tutte 17.695
article - articoli 0
book - libri 0
conference - conferenze 0
curatela - curatele 0
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 0
Totale 17.695
Salva come PNG Salva come JPEG


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2021/2022577 0 0 37 75 51 39 22 37 34 62 130 90
2022/2023791 89 110 42 107 40 65 20 50 129 16 63 60
2023/2024261 16 42 18 32 14 79 7 12 2 16 8 15
2024/2025720 39 73 46 74 116 30 52 9 28 69 25 159
2025/20261.950 146 144 144 169 240 104 172 94 435 162 77 63
2026/2027186 48 79 59 0 0 0 0 0 0 0 0 0
Totale 6.165